Novo Nordisk accepts fine from Danish public prosecutor over financial disclosure
Danish insulin giant Novo Nordisk (NOV: N) has accepted a fine of 500,000 kroner ($89,735), imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority.
In December 2013, the Danish Financial Supervisory Authority reported Novo Nordisk to the police for failing to disclose inside information as soon as possible, a violation of Section 27 (1) of the Danish Securities Trading Act. This related to Novo Nordisk failing to report its receipt of a Complete Response Letter from the US Food and Drug Administration on the evening of February 8, 2013, which was a Friday, in which the FDA stated it could not approve insulin products Tresiba and Ryzodeg.
The company published the decision on Sunday, February 10, but the Danish supervisory authorities decided it should have made the announcement on the Friday evening.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze